FCGR2B and cancer: The impact of FcγRIIb during the effector phase of infectious disease vaccination, including those for influenza viruses, remains unclear, although the FcγRIIb-mediated suppression is deleterious for direct-targeting antibody therapeutics against cancer (Roghanian et al., 2018).